Status:
COMPLETED
The Use of Low Molecular Weight Heparin in Hemodiafiltration
Lead Sponsor:
University Hospital, Ghent
Conditions:
Chronic Kidney Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Low molecular weight heparin (LMWH) is injected in the dialysis circuit at the start of the session. In the present study we compare 3 different methods of injection of LMWH: parameters of dialysis ef...
Eligibility Criteria
Inclusion
- chronic kidney disease stade V treated with hemodiafiltration
- age \>18 year
- Hematocrit \> 30%
Exclusion
- treatment with vitamin K antagonists
- treatment with other anti-coagulants or heparin besides the heparin used during dialysis
- active bleeding, infection or malignancy
- heparin associated allergy
- hepatic failure
- trombocytopenia \< 120.000/µl
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00756145
Start Date
September 1 2008
End Date
May 1 2015
Last Update
May 14 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Ghent
Ghent, Belgium, 9000